Prevelance of prostate cancer among Turkish men with prostate-specific antigen level of ≤100 ng/ml.

Prostate cancer (PCa) is one of the most common cancers among men and has become a significant health problem in developing and developed countries. Prostate-specific antigen (PSA) is a useful marker for screening and monitoring the patients. In this study, the author aimed to detect the prevalence of PCa among Turkish patients who underwent prostate biopsy with PSA level of <100 ng/ml.

The patients who underwent prostate biopsy between January 2008 and January 2015 were reviewed retrospectively. The clinical data that include age, PSA level, and biopsy results were recorded. The patients were divided into five groups according to the PSA levels; ≤4, 4.01-10, 10.01-20, 20.01-50, and 50.01-100 ng/ml.

There were 1609 patients in this study. Of these patients; 181, 914, 345, 129, and 40 patients had a PSA level of ≤4, 4.01-10, 10.01-20, 20.01-50, and 50.01-100 ng/ml, respectively. The patients' ages and PSA levels were between 40 and 89 years with a median of 62 ± 8.32 years and between 0.3 and 100 ng/ml with a median of 7.40 ± 12.97 ng/ml. PCa prevalence increased from 13.25% to 82.5% in the patients with a PSA level of ≤4 and 50.01-100 ng/ml.

Western populations have more common PCa than Asian men. The studies showed the PCa prevalence for Turkish men was higher than Asian and less than Western origins. Prevalence of PCa was increased with PSA level rising, and this prevalence is between Western and Asian origin similar in the literature.

Journal of cancer research and therapeutics. 0000 Jan [Epub]

Selahattin Çalışkan

Department of Urology, Hitit University Çorum Training and Research Hospital, Corum, Turkey.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe